Sol-Gel Technologies offers a highly asymmetric SGT-610 clinical option, with a $236.22 probability-weighted value versus $68.81 current price, but substantial binary and financing risk.
Overview
Sol-Gel Technologies is an Israeli specialty dermatology biotechnology company whose silica micro-encapsulation platform has produced two FDA-approved therapies, Twyneo for acne and Epsolay for rosacea. The company monetized the U.S. rights to both products through a $16.0 million Mayne Pharma transaction in April 2025, leaving a network of ex-U.S. partners and future royalty streams across Europe, Asia, Canada, and other markets. **The equity is now primarily an option on SGT-610**, a Phase 3, orphan- and breakthrough-designated 2% topical patidegib gel intended to prevent BCC lesions in Gorlin syndrome, an indication with no approved preventive drug. Q2 2026 revenue fell 96.6% year over year to $591,000 because Q2 2025 included the one-time Mayne proceeds, but expense discipline reduced R&D 20.0% to $3.719 million and G&A 25.3% to $1.034 million. Cash, deposits, and marketable securities totaled $49.3 million, funding operations into Q1 2028. **The key catalyst is late-November 2026 Phase 3 data**, followed potentially by an NDA in late 2027 and launch in late 2028. At approximately $254 million market capitalization and $207 million enterprise value, valuation reflects substantial clinical optionality rather than current sales.